NEW YORK (GenomeWeb) – Cepheid reported after the close of the market Thursday that its third quarter revenues increased 25 percent year over year.

The Sunnyvale, California-based molecular diagnostics firm, which signed a deal in September to be acquired by Danaher for around $4 billion, released its earnings through a quarterly report filed with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.